In vitro method for predicting mortality risk in patients suffering from shock
In vitro method for predicting mortality risk in patients suffering from shock. The present invention refers to the medical field. Particularly, it refers to an in vitro method for predicting mortality risk among patients suffering from shock, which comprises determining in a biological sample obtained from the patient the concentration level of specific proteins.
1 . A method of treating a human patient determined to have a mortality risk and who is suffering from cardiogenic shock, or who has suffered from cardiogenic shock, comprising:
treating the human patient having the mortality risk with a cardiogenic shock treatment, wherein the mortality risk has been determined by steps comprising:
a) obtaining a biological sample from the human patient, wherein the biological sample is a serum or plasma sample, or a combination thereof;
b) analyzing concentration levels of B2MG protein in a sample prepared from the biological sample, wherein the sample is analyzed by:
i) an enzyme-linked immunosorbent assay; or
ii) a mass spectrometry assay;
c) comparing the concentration levels of the B2MG protein as analyzed in step b) relative to levels of B2MG protein in a biological sample from a control survivor human patient suffering from cardiogenic shock as analyzed by the same assay; and
d) determining the mortality risk of the human patient, wherein an increased level of the B2MG with respect to the concentration level determined in the control survivor human patient suffering from cardiogenic shock is an indication of mortality risk.
2 . The method of claim 1 , wherein step b) further comprises analyzing concentration levels of L-FABP, and/or ALDOB and/or IC1 in the biological sample using the enzyme-linked immunosorbent assay or the mass spectrometry assay.
3 . The method of claim 1 , wherein step b) further comprises analyzing concentration levels of B2MG, L-FABP, ALDOB and IC1 in the biological sample using the enzyme-linked immunosorbent assay or the mass spectrometry assay.
4 . The method of claim 1 , wherein step b) further comprises analyzing concentration levels of FABPL, and/or ALDOB, and/or IC1, and/or F13A, and/or HPTR, and/or PLMN, and/or AACT, and/or ANGT, and/or FIBA, and/or FIBB, and/or FIBG, and/or CRP, and/or RET4, and/or S10A8, and/or HEP2, and/or IBP2, and/or MUC18, and/or SEPP1, and/or ILRL1, and/or FHR4, and/or CELR1, and/or MYO5A, and/or CATA, and/or ALDOA and/or APOB in the biological sample using the enzyme-linked immunosorbent assay or the mass spectrometry assay.
5 . The method of claim 1 , wherein the human patient is more than 75 years, has confusion at presentation, a previous myocardial infarction or coronary artery bypass grafting, acute coronary syndrome etiology and left ventricular ejection fraction of less than 40%, and the analytical method further comprises determining lactate and the estimated glomerular filtration rate (eGFRCKD-EPI).
6 . The method of claim 1 , wherein the method is performed within 24 hours from an admission of the human patient to a hospital.
7 . The method of claim 1 , wherein the method is performed within 90 days from an admission of the human patient to a hospital.
8 . A method of treating a human patient having a mortality risk and who is suffering from cardiogenic shock, or has suffered from cardiogenic shock, comprising:
treating the human patient having the mortality risk with a cardiogenic shock treatment, wherein the cardiogenic shock treatment comprises treatment with a ventricular assist device, revascularization, hemodynamic stabilization, treatment of multiorgan system dysfunction, administration of anti-arrhythmic agents, administration of synchronized cardioversion, administration of positive inotropic agents, administration of mechanical circulatory support, treatment using extracorporeal life support systems, heart transplantation, or any combination thereof;
and wherein the mortality risk has been determined by steps comprising:
a) obtaining a biological sample from the human patient, wherein the biological sample is a serum or plasma sample, or a combination thereof;
b) analyzing concentration levels of B2MG protein in the biological sample by: i) an enzyme-linked immunosorbent assay; or ii) a mass spectrometry assay;
c) comparing the concentration levels of the B2MG protein as analyzed in step b) relative to levels of B2MG protein in a biological sample from a control survivor human patient suffering from cardiogenic shock as analyzed by the same assay; and
d) determining the mortality risk, wherein an increased level of the B2MG with respect to the concentration level determined in the control survivor human patient suffering from cardiogenic shock is an indication of mortality risk.
9 . The method of claim 8 , wherein step b) further comprises determining the concentration level of the protein L-FABP, and/or ALDOB and/or IC1 in the biological sample obtained from the human patient, and step c) further comprises determining that a concentration level of the protein L-FABP or ALDOB is higher than the concentration a level of L-FABP or ALDOB in the control survivor human patient biological sample, and/or determining a level of the protein IC1 is lower than a concentration level of the protein IC1 in the control survivor human patient biological sample.
10 . The method of claim 8 , wherein step b) further comprises determining a concentration level of the proteins B2MG, L-FABP, ALDOB and IC1 in the biological sample obtained from the human patient, and step c) further comprises determining an increased level of the proteins B2MG, L-FABP and ALDOB relative to a level of B2MG, L-FABP and ALDOB, respectively, in the control survivor human patient biological sample, and further determining a decreased level of the protein IC1 relative to a level of IC1 in the control survivor human patient biological sample.
11 . The method of claim 8 , wherein step b) further comprises determining the concentration level of the proteins: FABPL, and/or ALDOB, and/or IC1, and/or F13A, and/or HPTR, and/or PLMN, and/or AACT, and/or ANGT, and/or FIBA, and/or FIBB, and/or FIBG, and/or CRP, and/or RET4, and/or S10A8, and/or HEP2, and/or IBP2, and/or MUC18, and/or SEPP1, and/or ILRL1, and/or FHR4, and/or CELR1, and/or MYO5A, and/or CATA, and/or ALDOA and/or APOB in the biological sample from the human patient.
12 . The method of claim 8 , wherein the human patient is more than 75 years, has confusion at presentation, a previous myocardial infarction or coronary artery bypass grafting, acute coronary syndrome etiology and left ventricular ejection fraction of less than 40%, and the analytical method further comprises determining lactate and the estimated glomerular filtration rate (eGFRCKD-EPI).
13 . The method of claim 8 , wherein the method is performed within 24 hours from an admission of the human patient to a hospital.
14 . The method of claim 8 , wherein the method is performed within 90 days from an admission of the human patient to a hospital.
15 . The method of claim 8 , wherein the determination of the concentration level of the B2MG protein is performed by ELISA, or by mass spectrometry.